TRLIX | VIVAX | TRLIX / VIVAX | |
Total Expense Ratio | 0.41 | 0.17 | 241% |
Annual Report Gross Expense Ratio | 0.41 | 0.17 | 241% |
Fund Existence | 23 years | 33 years | - |
Gain YTD | 8.650 | 6.512 | 133% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000000 | 3000 | 33,333% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 6.33B | 196B | 3% |
Annual Yield % from dividends | 1.36 | 2.06 | 66% |
Returns for 1 year | 7.87 | 7.90 | 100% |
Returns for 3 years | 20.24 | 25.93 | 78% |
Returns for 5 years | 54.20 | 68.56 | 79% |
Returns for 10 years | 44.39 | 114.64 | 39% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FPHAX | 24.89 | 0.35 | +1.43% |
Fidelity Select Pharmaceuticals Port | |||
QALGX | 37.48 | N/A | N/A |
Federated Hermes MDT Large Cap Growth A | |||
ETIEX | 13.46 | -0.01 | -0.07% |
Eventide Exponential Technologies I | |||
PEQSX | 37.57 | -0.08 | -0.21% |
Putnam Large Cap Value R6 | |||
LSRCX | 1.85 | -0.02 | -1.07% |
Lord Abbett Small Cap Value C |